Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IWWM-11 2022 | The value of treating smoldering Waldenström’s macroglobulinemia

Irene Ghobrial • 29 Oct 2022
IWWM-11 2022
Lymphoma Non-Hodgkin Lymphoma Rare Diseases Waldenström’s Macroglobulinemia

In this video, Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, shares some insights into the value of early interception in Waldenström’s macroglobulinemia (WM), and explains the importance of obtaining clinical trial data in this space and treating patients with smoldering WM before symptoms appear. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Irene Ghobrial

0:52
Using spatial proteomics to analyze the bone marrow microenvironment in SMM treated with nivolumab
Irene Ghobrial • 7 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
Early interception in SMM & novel agents being explored
Irene Ghobrial et al. • 25 Mar 2024
1:19
Single-cell sequencing of circulating tumor cells to predict progression from MGUS/SMM
Irene Ghobrial • 11 Dec 2023

Related Videos

2:00
BTK degraders in CLL and lymphoma: a Phase I trial of NX-5948
Dima El-Sharkawi • 28 Apr 2024
2:39
The role of bispecific antibodies in the treatment landscape for R/R DLBCL
Wendy Osborne • 22 Apr 2024
2:45
Continuity of care for patients with hematological predispositions to AML
Anupama Rao • 29 Apr 2024
1:23
The current treatment landscape for patients with T-cell prolymphocytic leukemia
Dima El-Sharkawi • 28 Apr 2024
The content of VJHemOnc is intended for healthcare professionals